CapsoVision (CV) EBITDA Margin (2024 - 2026)
CapsoVision (CV) posted EBITDA Margin of 190.51% for Q4 2025, up 15.95% sequentially from 226.65% in Q3 2025, and down 5626.0% YoY from 3.45% in Q4 2024.
CapsoVision (CV) EBITDA Margin (2024 - 2026) Analysis & Trends
CapsoVision has reported EBITDA Margin for 2 years, with the latest figure at 190.51% in Q4 2025.
- Quarterly EBITDA Margin fell 5626.0% year-over-year to 190.51% in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 174.14% (changed N/A YoY) and the FY2025 annual result came in at 188.25%, down 1883.0% from the prior year.
- EBITDA Margin improved to 190.51% in Q4 2025 per CV's latest filing, from 226.65% in the prior quarter.
- Over five years, EBITDA Margin peaked at 134.24% in Q4 2024 and troughed at 226.65% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 198.90 Bn | 193.29 Bn | 7.27 Bn | 13.44% |
| 2 | Stryker | 126.09 Bn | 122.62 Bn | 4.50 Bn | 25.18% |
| 3 | Medtronic | 118.39 Bn | 109.17 Bn | 6.41 Bn | 19.10% |
| 4 | Boston Scientific | 72.77 Bn | 72.24 Bn | 3.85 Bn | 21.65% |
| 5 | Edwards Lifesciences | 52.04 Bn | 47.78 Bn | 1.35 Bn | 29.48% |
| 6 | Dexcom | 34.42 Bn | 32.47 Bn | 830.00 Mn | 24.33% |
| 7 | GE HealthCare Technologies | 33.65 Bn | 31.54 Bn | 2.18 Bn | 13.96% |
| 8 | Koninklijke Philips | 26.29 Bn | 22.97 Bn | 4.55 Bn | 10.30% |
| 9 | Steris | 23.06 Bn | 22.57 Bn | 684.20 Mn | 19.15% |
| 10 | CapsoVision | 296.38 Mn | 287.30 Mn | 1.87 Mn | -208.07% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -208.07% |
| Dec 31, 2025 | -190.51% |
| Sep 30, 2025 | -226.65% |
| Jun 30, 2025 | -140.30% |
| Dec 31, 2024 | -134.24% |
| Sep 30, 2024 | -195.65% |
| Jun 30, 2024 | -185.40% |